

Financial Tearsheet

Company Overview

Neuropathix, Inc. is a biopharmaceutical medchem company focused on the research and development of a pipeline of patented socially responsible pain management therapeutics to treat patients with significant unmet medical needs. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases, chronic pain management and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
Jan 25, 2022	Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company's Scientific Advisory Board
Jan 18, 2022	Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
Nov 17, 2021	Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
Sep 28, 2021	Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded \$2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Aug 24, 2021	Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets

IR Contacts

Investor Relations

Investor Relations Firm
CORE IR
377 Oak Street
Garden City, NY 11530
(516) 222-2285
www.coreir.com
Contact: John Marco
Johnm@coreir.com

Transfer Agent

Securities Transfer Corp.
2901 Dallas Parkway, Suite 380, Plano, TX 75093
(469) 633-0101
www.stctransfer.com

Auditors

DBB McKennon
12790 El Camino Real #130
San Diego, CA 92130
(858) 217-4035
www.dbbmckennon.com











Corporate Counsel

Procopio, Cory, Hargreaves & Savitch LLP.
525 B Street, Suite 2200
San Diego, CA 92101
(619) 238-1900
www.procopio.com

Stock Performance

Stock Fundamentals	Value
Today's Open	0.0545
Volume	16,400
Day Range	0.0461 - 0.0545
52 Week Range	0.0381 - 0.4270
Bid/Ask	0.0000 / 0.0000
Bid/Ask Size	0 X 0
Previous Close	0.0472
Market Cap	4.06 million
Shares Outstanding	87.98 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.053500
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Aug 06, 2021	10-Q	Quarterly report	 
May 13, 2021	10-Q	Quarterly report	 
Mar 30, 2021	10-K	Annual report	 
Nov 12, 2020	10-Q	Quarterly report	 
Aug 12, 2020	10-Q	Quarterly report	 

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director